CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
Business Wire India CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at…